Daniel A. Landau
Expertise in
28
conditions

Dr. Daniel A. Landau

Hematology
169 Ashley Avenue, 2nd Floor, H268, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
28
conditions
169 Ashley Avenue, 2nd Floor, H268, 
Charleston, SC 

Overview

Dr. Daniel Landau is a board certified Hematologist/Oncologist. He has been in practice since 2011. Dr. Landau obtained his medical degree and residency from the University of South Florida College of Medicine and then completed his hematology/oncology fellowship at the Orlando Health Cancer Institute (previously a part of MD Anderson). Dr. Landau's has been at the forefront of managing both benign and malignant conditions. He has also served in a number of roles beyond being a clinician including the institution of a telehealth service within Orlando Health. He now joins MUSC in a telehealth role. Dr. Landau has also provided a major role in medical education, having trained physicians for more than a decade. Dr. Landau has been published/ presented research within the New England Journal of Medicine, American Society of Clinical Oncology and American society of Hematology.

Dr. Landau is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Non-Hodgkin Lymphoma, Myelofibrosis, Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 6 clinical trials. Dr. Landau is currently accepting new patients.

Graduate Institution

University Of South Florida College Of Medicine

Specialties

Hematology

Licenses

Internal Medicine in FL

Hospital Affiliations

Tidelands Waccamaw Community Hospital
Beaufort County Memorial Hospital
Musc Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

MUSC Health Telehealth Clinic - Charleston
169 Ashley Avenue, 2nd Floor, H268, Charleston, SC 29425

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
View 4 Less Clinical Trials

4 Total Publications

Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide added to leuprolide in a 73-year-old patient.
Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide added to leuprolide in a 73-year-old patient.
Journal: Clinical advances in hematology & oncology : H&O
Published: June 30, 2022
Similar Doctors
Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Hess is a Hematologist practicing medicine in Charleston, South Carolina. Dr. Hess is highly rated in 33 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Hess is currently accepting new patients.

Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Robert Stuart is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Stuart is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
28
conditions
Dr. Irl B. Greenwell
Hematology | Oncology
Expertise in
28
conditions
Dr. Irl B. Greenwell
Hematology | Oncology
Referral may be required

Charleston Hematology Oncology Associates PA

2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 
 (5.8 miles away)
843-577-6957
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Irl Greenwell is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Greenwell is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Greenwell is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel A. Landau

How do I make an appointment with Dr. Daniel A. Landau?

You can book an appointment with Dr. Daniel A. Landau by calling their office at 843-792-7097. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel A. Landau a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel A. Landau is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel A. Landau specialize in?

While Dr. Daniel A. Landau is a Hematology, they have specific expertise in Multiple Myeloma, Non-Hodgkin Lymphoma, and Myelofibrosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Daniel A. Landau participate in research or clinical trials?

Yes. Dr. Daniel A. Landau has published 4 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Daniel A. Landau's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel A. Landau accept my insurance?

Dr. Daniel A. Landau accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 843-792-7097 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Landau's expertise for a condition
ConditionClose
    View All 26 Advanced Conditions
    View All 63 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile